Intelligence desk

Products

Signal Tracker Data Platform Data Enrichment API

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
Encysive Pharmaceuticals logo — Leading the fight against vascular and inflammatory diseases...

Encysive Pharmaceuticals

Leading the fight against vascular and inflammatory diseases with groundbreaking synthetic and small molecule compounds.

Founded 1989 Private Equity Total: $88.95M Biotechnology, Pharmaceutical

General Information

Company Name Encysive Pharmaceuticals
Founded Year 1989
Industries Biotechnology, Pharmaceutical
Funding Stage Private Equity
Social

Get notified when Encysive Pharmaceuticals moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Encysive Pharmaceuticals

Encysive Pharmaceuticals, Inc. is a pioneering biopharmaceutical company focused on combatting vascular and inflammatory diseases through the development and commercialization of synthetic and small molecule compounds. The company's dedication to research and development is evident in its range of products, including Argatroban for treating heparin-induced thrombocytopenia, and Thelin (sitaxsentan sodium), designed to address pulmonary arterial hypertension, congestive heart failure, and essential hypertension. The clinical development pipeline features promising candidates such as TBC3711, TBC4746, ENC8003, and bimosiamose, targeting various receptors and conditions. Established in 1989 as Texas Biotechnology Corporation and rebranded to Encysive Pharmaceuticals, Inc. in 2003, the company has solidified research collaborations and licensing agreements with industry giants like GlaxoSmithKline plc, Mitsubishi Pharma Corporation, Schering-Plough, Ltd., Schering Corporation, and Revotar Biopharmaceuticals, AG. Notably, Encysive Pharmaceuticals received a significant $13.95MPrivate Equity Round investment on 20 August 2007, led by Enable Capital Management and Hudson Capital Group. Based in Houston, Texas, Encysive Pharmaceuticals, Inc. operated as a subsidiary of Pfizer Inc. as of June 10, 2008. The company's commitment to addressing critical medical needs and strategic collaborations positions it as a contender in the biotechnology and pharmaceutical industries.

Taxonomy: biopharmaceutical company, medical research, vascular diseases, inflammatory diseases, small molecule compounds, endothelin receptor antagonist, clinical development, therapeutic compounds, collaboration agreements, Pulmonary arterial hypertension, global medical needs, drug discovery, medical innovation

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Private Equity Round $13.95M 2
Enable Capital Management
Hudson Capital Group 		20 Aug 2007
Private Equity Round $75.00M 1 Azimuth Opportunity 19 Oct 2006

Encysive Pharmaceuticals Alternatives & Competitors

Encysive Pharmaceuticals vs
Pharmacopeia
Pharmacopeia

Innovating to meet critical health challenges with advanced therapeutic discoveries and developments...

Series Unknown
Biopharma, Biotechnology
Encysive Pharmaceuticals vs
EPIX Pharmaceuticals
EPIX Pharmaceuticals

Pioneering tomorrow's treatments for central nervous system and lung diseases with proprietary drug...

28 employees
Biotechnology, Health and Wellness
Encysive Pharmaceuticals vs
PhaseBio Pharmaceuticals, Inc.
PhaseBio Pharmaceuticals, Inc. United States

We're developing novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary...

Post Ipo Equity
10 employees
Biotechnology, Medical Devices

FAQ About Encysive Pharmaceuticals

Leading the fight against vascular and inflammatory diseases with groundbreaking synthetic and small molecule compounds.
Encysive Pharmaceuticals was founded in 1989.
Encysive Pharmaceuticals operates in the following industries: Biotechnology, Pharmaceutical.
Encysive Pharmaceuticals has completed 2 funding rounds, raising a total of $88.95M. The latest funding stage is Private Equity.
Top alternatives and competitors to Encysive Pharmaceuticals include Pharmacopeia, EPIX Pharmaceuticals, PhaseBio Pharmaceuticals, Inc., ImmuneCyte, Inc., VentiRx Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Encysive Pharmaceuticals and Pharmacopeia are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Encysive Pharmaceuticals and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy